

DEPARTMENT OF COMMERCE**Foreign-Trade Zones Board****[B-64-2020]****Foreign-Trade Zone (FTZ) 106—
Oklahoma City, Oklahoma;
Authorization of Production Activity;
Miraclon Corporation (Flexographic/
Aluminum Printing Plates and Direct/
Thermo Imaging Layer Film);
Weatherford, Oklahoma**

On October 27, 2020, Miraclon Corporation submitted a notification of proposed production activity to the FTZ Board for its facility within Subzone 106F, in Weatherford, Oklahoma.

The notification was processed in accordance with the regulations of the FTZ Board (15 CFR part 400), including notice in the **Federal Register** inviting public comment (85 FR 70580, November 5, 2020). On February 24, 2021, the applicant was notified of the FTZ Board's decision that no further review of the activity is warranted at this time. The production activity described in the notification was authorized, subject to the FTZ Act and the FTZ Board's regulations, including Section 400.14.

Dated: February 24, 2021.

Andrew McGilvray,

Executive Secretary.

[FR Doc. 2021-04102 Filed 2-26-21; 8:45 am]

BILLING CODE 3510-DS-P

DEPARTMENT OF COMMERCE**Foreign-Trade Zones Board****[B-13-2021]****Foreign-Trade Zone (FTZ) 72—
Indianapolis, Indiana; Notification of
Proposed Production Activity; XPO
Logistics (Wearable Electronic
Communication/Data Device Kitting);
Clayton, Indiana**

XPO Logistics (XPO) submitted a notification of proposed production activity to the FTZ Board for its facility in Clayton, Indiana. The notification conforming to the requirements of the regulations of the FTZ Board (15 CFR 400.22) was received on February 18, 2021.

The XPO facility is located within FTZ 72. The facility is used for the kitting of wearable electronic communication/data devices with watch bands of various materials. Pursuant to 15 CFR 400.14(b), FTZ activity would be limited to the specific foreign-status materials and components and specific finished product described

in the submitted notification (as described below) and subsequently authorized by the FTZ Board.

Production under FTZ procedures could exempt XPO from customs duty payments on the foreign-status components used in export production. On its domestic sales, for the foreign-status materials/components noted below, XPO would be able to choose the duty rate during customs entry procedures that applies to wearable electronic communication/data devices (duty-free). XPO would be able to avoid duty on foreign-status components which become scrap/waste. Customs duties also could possibly be deferred or reduced on foreign-status production equipment.

The components and materials sourced from abroad include wearable electronic communication/data devices and watch bands of leather, steel, silicon and woven nylon textile material (duty rate ranges from duty-free to 11.2%). The request indicates that certain materials/components are subject to duties under Section 301 of the Trade Act of 1974 (Section 301), depending on the country of origin. The applicable Section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41).

Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: ftz@trade.gov. The closing period for their receipt is April 12, 2021.

A copy of the notification will be available for public inspection in the "Reading Room" section of the Board's website, which is accessible via www.trade.gov/ftz.

For further information, contact Diane Finver at Diane.Finver@trade.gov.

Dated: February 24, 2021.

Andrew McGilvray,

Executive Secretary.

[FR Doc. 2021-04103 Filed 2-26-21; 8:45 am]

BILLING CODE 3510-DS-P

DEPARTMENT OF COMMERCE**Foreign-Trade Zones Board****[B-12-2021]****Foreign-Trade Zone (FTZ) 5—Seattle,
Washington; Notification of Proposed
Production Activity; Juno
Therapeutics, Inc.
(Biopharmaceuticals); Bothell,
Washington**

Juno Therapeutics, Inc. (Juno) submitted a notification of proposed

production activity to the FTZ Board for its facility in Bothell, Washington. The notification conforming to the requirements of the regulations of the FTZ Board (15 CFR 400.22) was received on February 12, 2021.

A separate application has been submitted for FTZ designation at the company's facility under FTZ 5. The facility is used for the production of cell therapy products. Pursuant to 15 CFR 400.14(b), FTZ activity would be limited to the specific foreign-status material and specific finished product described in the submitted notification (as described below) and subsequently authorized by the FTZ Board.

Production under FTZ procedures could exempt Juno from customs duty payments on the foreign-status material used in export production. On its domestic sales, for the foreign-status material noted below, Juno would be able to choose the duty rate during customs entry procedures that applies to cell therapy products (duty-free). Juno would be able to avoid duty on foreign-status material which becomes scrap/waste. Customs duties also could possibly be deferred or reduced on foreign-status production equipment. The material sourced from abroad is human primary cells ("T-cells") (duty-free).

Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: ftz@trade.gov. The closing period for their receipt is April 12, 2021.

A copy of the notification will be available for public inspection in the "Reading Room" section of the Board's website, which is accessible via www.trade.gov/ftz.

For further information, contact Diane Finver at Diane.Finver@trade.gov or (202) 482-1367.

Dated: February 22, 2021.

Andrew McGilvray,

Executive Secretary.

[FR Doc. 2021-04104 Filed 2-26-21; 8:45 am]

BILLING CODE 3510-DS-P

DEPARTMENT OF COMMERCE**International Trade Administration****Antidumping or Countervailing Duty
Order, Finding, or Suspended
Investigation; Opportunity To Request
Administrative Review**

AGENCY: Enforcement and Compliance, International Trade Administration, Department of Commerce.

FOR FURTHER INFORMATION CONTACT: Brenda E. Brown, Office of AD/CVD